| Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial V Diéras, HS Han, B Kaufman, H Wildiers, M Friedlander, JP Ayoub, ... The lancet oncology 21 (10), 1269-1282, 2020 | 267 | 2020 |
| Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial AB Lassman, SL Pugh, TJC Wang, K Aldape, HK Gan, M Preusser, ... Neuro-oncology 25 (2), 339-350, 2023 | 86* | 2023 |
| refund: Regression with functional data C Crainiceanu, P Reiss, J Goldsmith, L Huang, L Huo, F Scheipl, ... R package version 0.1-6, 2012 | 78 | 2012 |
| The effect of water activity and storage temperature on the growth of Aspergillus flavus in medicinal herbs R Kulshrestha, CP Gupta, G Shukla, MG Kundu, SP Bhatnagar, ... Planta medica 74 (10), 1308-1315, 2008 | 39 | 2008 |
| Effect of contact precautions for MRSA on patient satisfaction scores DJ Livorsi, MG Kundu, B Batteiger, AB Kressel Journal of Hospital Infection 90 (3), 263-266, 2015 | 28 | 2015 |
| Regression trees for longitudinal data with baseline covariates MG Kundu, J Harezlak Biostatistics & epidemiology 3 (1), 1-22, 2019 | 25 | 2019 |
| Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of … HS Han, BK Arun, B Kaufman, H Wildiers, M Friedlander, JP Ayoub, ... Annals of Oncology 33 (3), 299-309, 2022 | 23 | 2022 |
| Efficacy and safety of first-line veliparib and carboplatin–paclitaxel in patients with HER2− advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical … BK Arun, HS Han, B Kaufman, H Wildiers, M Friedlander, JP Ayoub, ... European Journal of Cancer 154, 35-45, 2021 | 20* | 2021 |
| Longitudinal functional models with structured penalties MG Kundu, J Harezlak, TW Randolph Statistical modelling 16 (2), 114-139, 2016 | 20 | 2016 |
| Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non–Squamous Non–Small Cell Lung Cancer R Govindan, M Lind, A Insa, SA Khan, D Uskov, A Tafreshi, S Guclu, J Bar, ... Clinical Lung Cancer 23 (3), 214-225, 2022 | 17 | 2022 |
| Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors JC Yao, JA Chan, AC Mita, MG Kundu, K Hermosillo Reséndiz, K Hu, ... OncoTargets and therapy, 3177-3186, 2017 | 16 | 2017 |
| Methicillin-resistant Staphylococcus aureus (MRSA) nasal real-time PCR: a predictive tool for contamination of the hospital environment DJ Livorsi, S Arif, P Garry, MG Kundu, SW Satola, TH Davis, B Batteiger, ... infection control & hospital epidemiology 36 (1), 34-39, 2015 | 16 | 2015 |
| Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced … SL Puhalla, V Diéras, BK Arun, B Kaufman, H Wildiers, HS Han, JP Ayoub, ... Clinical Cancer Research 27 (18), 4983-4993, 2021 | 13* | 2021 |
| Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent … PMJ Clement, L Dirven, M Eoli, JM Sepulveda-Sanchez, ... European Journal of Cancer 147, 1-12, 2021 | 13 | 2021 |
| Specificity and sensitivity of normality tests MG Kundu, S Mishra, D Khare Proceedings of the VI International Symposium on Optimisation and Statistics, 2011 | 12 | 2011 |
| Analysis of the potential risk of central intravenous lines and/or total parenteral nutrition with ventriculoatrial shunts IK White, KA Shaikh, OM Nyarenchi, MG Kundu, JC Boaz, DH Fulkerson Child's Nervous System 31, 563-568, 2015 | 11 | 2015 |
| Phase I, two-part, multicenter, first-in-human (FIH) study of DS-6000a in subjects with advanced renal cell carcinoma (RCC) and ovarian tumors (OVC). EP Hamilton, S Jauhari, KN Moore, BI Rini, R McLeod, J Lin, N Izumi, ... Journal of Clinical Oncology 40 (16_suppl), 3002-3002, 2022 | 9 | 2022 |
| Survival trees based on heterogeneity in time‐to‐event and censoring distributions using parameter instability test MG Kundu, S Ghosh Statistical Analysis and Data Mining: The ASA Data Science Journal, 2021 | 8 | 2021 |
| Surrogacy of progression free survival for overall survival in metastatic breast cancer studies: meta-analyses of published studies MG Kundu, S Acharyya Contemporary clinical trials 53, 20-28, 2017 | 7 | 2017 |
| 140O veliparib plus carboplatin-paclitaxel in patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer: results in hormone receptor-positive and triple … JP Ayoub, ML Friedlander, VC Dieras, H Wildiers, B Arun, HS Han, ... Annals of Oncology 31, S65, 2020 | 6 | 2020 |
hans wildiershoogleraar UZLeuvenVerified email at uzleuven.be
